All In Biotech

Drug Trial Radar · NCT04603976

Registry for Migraine - Clinical Core

Last checked: Nov 20, 2026Latest source record: Oct 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 25, 2020

Primary completion

Oct 2022

Study completion Oct 2022

Sponsor

Lead sponsor
Danish Headache CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate the effect of erenumab on efficacy outcomes, tolerability outcomes, and patient-reported outcomes in individuals with migraine. Furthermore, the study aims to identify clinical predictors of erenumab response.

Conditions

  • Migraine

Interventions

  • ErenumabDrug

    Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Headache DiaryTime frame: Baseline Phase (Day -28 to Day 1) to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Danish Headache Center

    Glostrup Municipality, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.